查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1750679

全球肝癌诊断市场：市场规模、市场份额、趋势分析（按测试类型、最终用途和地区）、细分市场预测（2025-2030 年）

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肝癌诊断市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球肝癌诊断市场规模预计到2030年将达到146.7632亿美元，2025年至2030年的复合年增长率为6.67%。

肝癌盛行率的不断上升、诊断技术的进步以及对筛检对治疗和存活率重要性的认识正在推动肝癌诊断市场的成长。

根据美国癌症协会的统计，预计 2022 年将诊断出约 41,260 例新的肝癌病例。此外，根据 Globocan 2020 年的报告，全球约有 830,180 人将死于肝癌。世界卫生组织也估计，慢性肝炎病毒感染在人群中广泛存在，约有 5800 万人感染C型肝炎病毒(HCV)。 HCV 和B型肝炎病毒 (HBV) 是肝癌最常见的危险因子。此外，感染或接触肝硬化和吸烟等其他危险因子将激增对筛检解决方案的需求，以便早期治疗和诊断肝癌，提高存活率。因此，预测期内对诊断产品的需求将上升，推动市场成长。

COVID-19 疫情扰乱了肝癌患者的治疗，导致死亡率上升。筛检和治疗的延误和中断也对肝癌患者产生了影响。例如，在 2021 年 6 月的一篇论文中，来自欧洲国家的研究人员评估了疫情对肝癌患者日常医疗照护的影响，并得出结论，这些调整显着改变了治疗结果。然而，在 COVID-19 疫情期间，技术的进步和对免疫系统的更深入理解，促成了许多新的医疗诊断方法的推出。此外，疫情也提高了人们对健康的重视，促使人们定期进行健康检查，以便及早诊断和治疗。

诊断技术的进步得益于世界各地许多公共和私人机构的认知提升和支持倡议。这将促进各种癌症的筛检和诊断，并有望推动诊断解决方案的成长。例如，2022年9月，美国诊断公司Delfi Diagnostics, Inc.宣布，已被选为欧洲一项大规模筛检试验的液态切片合作伙伴。

为了满足对肝癌早期检测创新解决方案日益增长的需求，多家公司正在推出新产品。例如，2020年3月，罗氏公司荣获「突破性设备」奖。罗氏公司凭藉其全新的Elecsys GALAD评分系统获得了美国食品药物管理局（FDA）颁发的「突破性设备称号」。此评分系统透过向临床医生提供及时准确的信息，支持肝细胞癌（HCC）的诊断。各大公司也在寻求联合研究、合约和合作伙伴关係，以开发新产品。此类产品开发和市场拓展将加剧市场竞争，并促进肝癌诊断市场的成长。

肝癌诊断市场：分析概述

  • 从检测类型来看，由于对精准且经济高效的疾病分期的需求不断增长，实验室检测在2024年占据了最大份额。此外，用于监测治疗方案疗效的实验室检测应用也推动了这一成长。
  • 根据最终用途，医院和诊断实验室部门在 2024 年占据了市场主导地位。人们倾向于将这些环境作为在医疗专业人员的帮助下进行诊断和治疗的初级保健中心，这推动了这一部门的成长。
  • 由于人口中风险因素的普遍存在，北美将在2024年占据最高份额。这是因为该地区对疾病筛检的认识不断提高，以及先进技术的采用推动了这一成长。
  • 预测期内，亚太地区将呈现最快的复合年增长率。此外，新兴经济体将推动该地区新兴国家对诊断检测的采用。

目录

第一章 分析方法与范围

第二章执行摘要

第三章肝癌诊断市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 肝癌诊断市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章肝癌诊断市场：按测试类型估计和趋势分析

  • 细分仪表板
  • 肝癌诊断市场：依检测类型进行波动分析
  • 肝癌诊断市场规模及依检测类型趋势分析（2018-2030）
    • 全球临床检测市场（2018-2030）
    • 影像学诊断
    • 内视镜检查
    • 切片检查

第五章肝癌诊断市场：依最终用途的估计和趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球肝癌诊断市场：依最终用途分類的展望
  • 市场规模预测及趋势分析（2018-2030年）
  • 医院和诊断实验室
    • 全球医院和诊断实验室市场（2018-2030）
  • 学术研究所
    • 全球学术研究机构市场（2018-2030）
  • 製药/CRO实验室
    • 全球製药和 CRO 实验室市场（2018-2030 年）

第六章肝癌诊断市场：按地区估计和趋势分析

  • 各地区市场占有率分析（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 全球市场概况：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 最新趋势和影响分析：按主要製造商
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 主要企业市场占有率分析（2024年）
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Qiagen NV
    • Siemens Healthineers
    • Becton, Dickinson &Company
    • Illumina, Inc.
    • Epigenomics AG
    • Koninklijke Philips NV
    • Fujifilm Medical Systems USA, Inc.
Product Code: GVR-3-68038-012-5

Liver Cancer Diagnostics Market Growth & Trends:

The global liver cancer diagnostics market size is estimated to reach USD 14,676.32 million by 2030, registering a CAGR of 6.67% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

The COVID-19 pandemic disrupted liver cancer patient care and resulted in higher mortality rates. The delayed or interrupted screening & procedures impacted the patients with the disease. For example, in a June 2021 article, researchers from European countries assessed the pandemic's impact on routine care of liver cancer patients and concluded that the modifications significantly altered the outcomes. However, with advancements in technology and a better understanding of the immune system during COVID-19, many new healthcare diagnostic products have been launched. Moreover, the pandemic boosted the importance of health and pushed the population toward regular health screening for early diagnosis & treatment.

The technological advancement in diagnosis has resulted from increased awareness and supportive initiatives by many public-private organizations worldwide. This will result in a conducive environment to increase the screening as well as diagnosis of various cancers and is expected to propel the growth of diagnostics solutions. For example, in September 2022, Delfi Diagnostics, Inc., a U.S.-based diagnostics company, announced that it has been selected as the liquid biopsy partner in a large-scale screening trial in Europe.

To cater to the increased demand for innovative solutions for the early detection of liver cancer, multiple companies are launching new products. For instance, in March 2020, F. Hoffmann-La Roche Ltd. Roche received the 'Breakthrough Device Designation' from the US FDA for its new Elecsys GALAD score. The score supports clinicians in the diagnosis of hepatocellular carcinoma (HCC) by providing them with timely and accurate information. Key companies are also undergoing collaborations, agreements, and partnerships for new product developments. Such product developments & launches will intensify the market competition and fuel the market growth for liver cancer diagnostics.

Liver Cancer Diagnostics Market Report Highlights:

  • On the basis of test type, laboratory tests held the largest share in 2024, owing to the increased demand for accurate & cost-effective diagnosis of disease stages. In addition, the application of laboratory tests for monitoring response to treatment plans also propels the growth
  • Based on end-use, the hospitals and diagnostic laboratories segment dominated the market in 2024. The preference for these settings as primary care centers for the diagnosis and treatment with the help of medical professionals boosts the segment's growth
  • North America accounted for the highest share in 2024, due to the prevalence of risk factors in the population. This has resulted from the increased awareness about disease screening and the growing adoption of advanced technologies in this region, driving the growth
  • Asia Pacific will exhibit the fastest CAGR during the forecast period, owing to the prevalence of diseases and the presence of a large geriatric population in the region. In addition, the developing economies will boost the adoption of diagnostic tests in the region's emerging countries.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Incidence of Liver Cancer
      • 3.2.1.2. Technological Advancements
      • 3.2.1.3. Extensive R&D For Developing Novel Testing Solutions
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic imaging
  • 3.3. Liver Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Liver Cancer Diagnostics Market: Test type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Cancer Diagnostics Market: Product Movement Analysis
  • 4.3. Liver Cancer Diagnostics Market Size & Trend Analysis, by test type, 2018 to 2030 (USD Million)
    • 4.3.1. Global Laboratory Tests Market, 2018 - 2030 (USD Million)
      • 4.3.1.1. Biomarkers
        • 4.3.1.1.1. Global biomarkers market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.1. Oncofetal and Glycoprotein Antigens
            • 4.3.1.1.1.1.1. Global oncofetal and glycoprotein antigens market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.2. Enzymes and Isoenzymes
            • 4.3.1.1.1.2.1. Global enzymes and isoenzymes market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.3. Growth Factors and Receptors
            • 4.3.1.1.1.3.1. Global growth factors and receptors market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.4. Molecular Markers
            • 4.3.1.1.1.4.1. Global molecular markers market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.5. Pathological Biomarkers
            • 4.3.1.1.1.5.1. Global pathological biomarkers market, 2018 - 2030 (USD Million)
      • 4.3.1.2. Blood Tests
        • 4.3.1.2.1. Global blood tests market, 2018 - 2030 (USD Million)
    • 4.3.2. Imaging
      • 4.3.2.1. Global Imaging Market, 2018 - 2030 (USD Million)
    • 4.3.3. Endoscopy
      • 4.3.3.1. Global Endoscopy Market, 2018 - 2030 (USD Million)
    • 4.3.4. Biopsy
      • 4.3.4.1. Global Biopsy Market, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Liver Cancer Diagnostics Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Hospitals & Diagnostic Laboratories
    • 5.5.1. Global Hospitals & Diagnostic Laboratories market, 2018 - 2030 (USD Million)
  • 5.6. Academic & Research Institutes
    • 5.6.1. Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 5.7. Pharmaceutical & CRO Laboratories
    • 5.7.1. Global Pharmaceutical & CRO Laboratories market, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. North America: SWOT Analysis
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/Reimbursement
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/Reimbursement
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/Reimbursement
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe: SWOT Analysis
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/Reimbursement
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/Reimbursement
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/Reimbursement
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/Reimbursement
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/Reimbursement
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/Reimbursement
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/Reimbursement
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/Reimbursement
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific: SWOT Analysis
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/Reimbursement
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/Reimbursement
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/Reimbursement
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/Reimbursement
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/Reimbursement
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/Reimbursement
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America: SWOT Analysis
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/Reimbursement
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/Reimbursement
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA: SWOT Analysis
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/Reimbursement
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/Reimbursement
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/Reimbursement
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Abbott Laboratories
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Services benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Thermo Fisher Scientific, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Services benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. F. Hoffmann-La Roche Ltd.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Services benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Qiagen N.V.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Services benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Siemens Healthineers
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Services benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Becton, Dickinson & Company
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Services benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Illumina, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Services benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Epigenomics AG
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Services benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Koninklijke Philips N.V.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Services benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Fujifilm Medical Systems U.S.A., Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Services benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Liver cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 North America Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 5 U.S Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 6 U.S Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 7 Canada Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 Canada Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 9 Mexico Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 10 Mexico Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 11 Europe Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 12 Europe Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 13 UK Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 14 UK Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 15 Germany Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 16 Germany Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 17 France Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 18 France Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 19 Italy Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 20 Italy Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 21 Spain Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 22 Spain Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 23 Denmark Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 24 Denmark Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 25 Sweden Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 26 Sweden Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 27 Norway Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 28 Norway Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 31 Japan Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 Japan Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 33 China Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 34 China Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 35 India Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 India Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 37 Australia Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Australia Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 39 South Korea Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 40 South Korea Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 41 Thailand Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Thailand Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 43 Latin America Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 44 Latin America Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 45 Brazil Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 46 Brazil Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 47 Argentina Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 48 Argentina Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 49 MEA Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 50 MEA Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 51 South Africa Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 52 South Africa Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 55 UAE Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 56 UAE Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Liver cancer diagnostics market: market outlook
  • Fig. 14 Liver cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Liver cancer diagnostics market driver impact
  • Fig. 20 Liver cancer diagnostics market restraint impact
  • Fig. 21 Liver cancer diagnostics market strategic initiatives analysis
  • Fig. 22 Liver cancer diagnostics market: Test type movement analysis
  • Fig. 23 Liver cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 24 Laboratory Tests Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 25 Imaging Liver Cancer Diagnostics estimates and forecast, 2018 - 2030
  • Fig. 26 Endoscopy Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 27 Biopsy Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 28 Liver cancer diagnostics market: End-use movement analysis
  • Fig. 29 Liver cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 30 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 31 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
  • Fig. 32 Pharmaceutical & CRO Laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global Liver cancer diagnostics market: Regional movement analysis
  • Fig. 34 Global Liver cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 35 Global Liver cancer diagnostics market share and leading players
  • Fig. 36 North America market share and leading players
  • Fig. 37 Europe market share and leading players
  • Fig. 38 Asia Pacific market share and leading players
  • Fig. 39 Latin America market share and leading players
  • Fig. 40 Middle East & Africa market share and leading players
  • Fig. 41 North America: SWOT
  • Fig. 42 Europe SWOT
  • Fig. 43 Asia Pacific SWOT
  • Fig. 44 Latin America SWOT
  • Fig. 45 MEA SWOT
  • Fig. 46 North America, by country
  • Fig. 47 North America
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S.
  • Fig. 50 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 51 Canada
  • Fig. 52 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 53 Mexico
  • Fig. 54 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 55 Europe
  • Fig. 56 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 57 UK
  • Fig. 58 UK market estimates and forecasts, 2018 - 2030
  • Fig. 59 Germany
  • Fig. 60 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 61 France
  • Fig. 62 France market estimates and forecasts, 2018 - 2030
  • Fig. 63 Italy
  • Fig. 64 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 65 Spain
  • Fig. 66 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 67 Denmark
  • Fig. 68 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 69 Sweden
  • Fig. 70 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 71 Norway
  • Fig. 72 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 73 Asia Pacific
  • Fig. 74 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 75 China
  • Fig. 76 China market estimates and forecasts, 2018 - 2030
  • Fig. 77 Japan
  • Fig. 78 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 79 India
  • Fig. 80 India market estimates and forecasts, 2018 - 2030
  • Fig. 81 Thailand
  • Fig. 82 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 83 South Korea
  • Fig. 84 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 85 Australia
  • Fig. 86 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 87 Latin America
  • Fig. 88 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 89 Brazil
  • Fig. 90 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 91 Argentina
  • Fig. 92 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 93 Middle East and Africa
  • Fig. 94 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 95 South Africa
  • Fig. 96 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 97 Saudi Arabia
  • Fig. 98 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 99 UAE
  • Fig. 100 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 101 Kuwait
  • Fig. 102 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 103 Market share of key market players- Liver cancer diagnostics market